June 3, 2020 / 12:14 PM / a month ago

BRIEF-Beigene Reports Approval Of Brukinsa In China For Small Lymphocytic Lymphoma

June 3 (Reuters) - Beigene Ltd:

* BEIGENE ANNOUNCES THE APPROVAL OF BRUKINSA™ (ZANUBRUTINIB) IN CHINA FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA AND RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

* BEIGENE LTD - RECOMMENDED DOSE OF BRUKINSA IN CHINESE PACKAGE INSERT IS 160 MG TWICE DAILY TAKEN ORALLY WITH OR WITHOUT FOOD Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below